Adults with COPD who used inhaled corticosteroids for more than 24 months faced higher risks for diabetes, osteoporosis, ...

Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...

Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.

Eligible patients had COPD, were ages 40 or older, and were new initiators of these inhalers from 2021 to 2023. They were ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

Medscape Medical News, August 08, 2023 Study Questions Use of Branded Inhalers for COPD Researchers said their analysis found that a generic product approved in 2019 was equally effective as the ...

COPD is term used to describe a number of progressive lung ... As well as reduced exacerbations, the trial also found that the new inhaler helped to improve lung function more generally and resulted ...

With Medicare coverage, a person can still have certain out-of-pocket costs for an inhaler. Out-of-pocket cost: This is the amount a person must pay for care when Medicare does not pay the total ...

Inhaler misuse leading to inadequate medication delivery impacts a person's ability to manage symptoms of chronic obstructive pulmonary disease (COPD), and additional education about proper ...

Background and Goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma ...